Innovent Biopharmaceutical Transformation
Commercial: Expanded Strategic Partnership with Lilly in Oncology
in Commercialization of Multiple Late-Stage Products
Expand Innovent and Lilly's strategic partnership in oncology
including multiple late-stage products
✓ Further validates Innovent's commercial platform and capability
Further expand Innovent's rich oncology pipeline by adding
one approved product, one NDA product, and potentially a
one late stage product, providing integrated patient
solutions with strong portfolio synergies
Enhance Innovent's franchise in major cancer indications
including NSCLC, GC and HCC, as well as potentially
hematological malignancies
Innovent will receive...
• Sole commercialization rights to import, market,
promote, distribute and detail CyramzaⓇ
(ramucirumab) and RetsevmoⓇ(selpercatinib) in
mainland China
Right of first negotiation granted to Innovent for
potential future commercialization of
pirtobrutinib in mainland China
CYRAMZA™
ramucirumab injection
10 mg/ml solution
China approval for GC in Mar 2022,
NDA for HCC submitted in Sep 2021
Retevmo™
China NDA submitted in
Aug 2021
Pirtobrutinib
(Global Phase 3 ongoing)
GC
HCC
NSCLC
new case
new case
480K
410K
new case
650K
Late-stage
DTC/MTC
Pirtobrutinib
new case
is an Orally Active,
Highly Selective and non-Covalent BTK Inhibitor
4
58K
Leverage two parties' strengths in a win-win manner to continue bringing innovative
medicines to benefit Chinese patients
Innovent
Confidential
Copyright©2022 Innovent
Lilly
Will receive...
Upfront payment - $45m in total upon
regulatory approvals of CyramzaⓇ in HCC and
RetsevmoⓇ in NSCLC
• Responsible for manufacturing and supply of
CyramzaⓇ and RetsevmoⓇ
7View entire presentation